earnings
CE
NASDAQ · CELZ
Creative Medical Technology Holdings, Inc.
Healthcare · Biotechnology
$0.89
Down-$0.02 (-2.24%)
Updated Sep 16, 2026, 6:16 PM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.75M
- P/E ratio
- -1
- Dividend yield
- 0.00%
- 52-week range
- $0.62 – $4.72
- Volume
- 118.84K
- Avg. volume
- 99.26K
Price performance
CELZ price history
1M range · 20 trading sessions · Daily adjusted prices
CELZ closed at $0.89 after 20 trading sessions, down 18.06% for the selected period.
- Last close
- $0.89
- Period change
- -18.06%
- Period low
- $0.88
- Period high
- $1.31
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $0.9168 | $0.9723 | $0.85 | $0.885 | 118.84K |
| Sep 14, 2026 | $0.9513 | $0.9728 | $0.8559 | $0.8779 | 404.25K |
| Sep 11, 2026 | $0.95 | $0.998 | $0.95 | $0.9606 | 101.16K |
| Sep 10, 2026 | $1.05 | $1.0557 | $0.9363 | $0.9502 | 320.5K |
| Sep 9, 2026 | $1.08 | $1.085 | $1.04 | $1.04 | 109.08K |
| Sep 8, 2026 | $1.10 | $1.12 | $1.07 | $1.08 | 140.6K |
| Sep 4, 2026 | $1.06 | $1.12 | $1.06 | $1.11 | 151.65K |
| Sep 3, 2026 | $1.14 | $1.14 | $1.04 | $1.06 | 179.14K |
| Sep 2, 2026 | $1.10 | $1.15 | $1.10 | $1.13 | 94.58K |
| Sep 1, 2026 | $1.11 | $1.13 | $1.09 | $1.10 | 107.78K |
| Aug 31, 2026 | $1.14 | $1.19 | $1.09 | $1.13 | 246.55K |
| Aug 28, 2026 | $1.17 | $1.18 | $1.115 | $1.14 | 198.97K |
| Aug 27, 2026 | $1.20 | $1.21 | $1.1201 | $1.14 | 249.49K |
| Aug 26, 2026 | $1.22 | $1.25 | $1.19 | $1.19 | 252.86K |
| Aug 25, 2026 | $1.19 | $1.26 | $1.19 | $1.24 | 171.19K |
| Aug 24, 2026 | $1.29 | $1.29 | $1.1901 | $1.21 | 387.17K |
| Aug 21, 2026 | $1.27 | $1.35 | $1.22 | $1.31 | 549.05K |
| Aug 20, 2026 | $1.28 | $1.43 | $1.08 | $1.28 | 10.26M |
| Aug 19, 2026 | $1.08 | $1.17 | $1.08 | $1.12 | 605.01K |
| Aug 18, 2026 | $1.07 | $1.13 | $1.06 | $1.08 | 314.91K |
Latest CELZ news
The latest Smart Investors Daily articles mentioning CELZ.
Stock researchResearch & News · Analysis
Loading stock research…

